Hong Kong participating insurance, taken apart: structure, commissions, sales scripts, and how it compares to just investing

1. What a participating policy is

A participating policy is a savings-type life insurance product whose return has two parts:

• The guaranteed part: usually very low, about 1%.
• The non-guaranteed dividend part: declared each year by the insurer based on its own investment performance. It is an “illustrated benefit”, not a promised return.

The 6 to 7% long-term IRR shown at the point of sale is an illustration you might only approach after holding for 20 to 30 years. Early cash values sit far below the premiums paid, and break-even typically takes 15 to 20 years.

From 2025 the Hong Kong Insurance Authority has capped illustrated returns: US-dollar products from 7.2% down to 6.5%, Hong Kong-dollar products to 6%, in an effort to rein in a competitive free-for-all.

2. Commission structure: how much does the broker really make?

This is a matter of public record in the industry:

• Before reform, first-year commission on participating policies (including incentives) could reach 100% of first-year premium or more, falling off a cliff in years two and three.
• New Insurance Authority rules (effective January 2026): first-year commission may not exceed 70% of total commission, with the remainder spread evenly over policy years two to six.
• Bank channels are phased in: an 85% cap from July 2027, dropping to 70% from July 2028.
• Commission ultimately comes out of the premium itself. It is part of how the product is priced, and it directly slows the growth of cash value.

Conclusion: the regulator itself has characterised the old commission structure as the root of “sales misconduct”. Exaggerated returns, pressure selling and offshore referrals all trace back to it.

3. Does the “cross-border asset allocation” pitch hold up?

The key clarification: a Hong Kong policy is not a channel for legally turning mainland renminbi into offshore US-dollar assets.

• The individual annual foreign-exchange quota is US$50,000 per person; a large policy (say US$140,000, about RMB 1 million) exceeds one person’s quota.
• The compliant precondition is that you already have lawful offshore funds: offshore income, previously converted deposits, or proceeds from offshore assets.
• Pooling several family members’ quotas (“ant moving”) is explicitly prohibited and enforced against.
• So “cross-border asset allocation” is only true for people who already hold offshore assets. For an ordinary person trying to turn mainland renminbi deposits directly into offshore assets, this route does not work within the rules.

4. Tax and inheritance: the real picture

CRS: a common piece of misdirection

Many sales scripts hint that “a Hong Kong policy avoids CRS reporting”. That is not accurate:

• Hong Kong has implemented CRS since 2017, and Hong Kong insurers count as financial institutions.
• Every policy with cash value (participating, savings life, and so on) is a reportable financial account under CRS.
• Cash value, dividends and surrender value are reported annually to the Hong Kong tax authority and exchanged with the mainland tax authority.
• Only pure protection products with no cash value (term life, medical) fall outside reporting.

Conclusion: a participating savings policy addresses asset structure and convenience of inheritance. It is not a tool for hiding assets or avoiding tax.

Is inheritance on the mainland really that hard?

With a valid will, the law says the will governs, but in practice:

• Large bank deposits (usually above RMB 50,000) and property transfers still generally require a notarised certificate of inheritance.
• That requires the death certificate, the will, and proof of identity and kinship for every statutory heir.
• The notary office checks for other potential heirs and the will’s validity; the process can take weeks to months.

For an ordinary family with simple relationships and no expected disputes, that cost is far lower than the cost of a high-commission policy.

The insurance advantage is real: with a named beneficiary, the death benefit goes directly to the beneficiary, bypassing probate or notarised inheritance, and can be paired with an insurance trust for staged payouts.

Conclusion: this feature only pays off for high-net-worth families with large estates and complicated relationships (multiple marriages, cross-border heirs). For an ordinary family, a properly drafted will and the normal inheritance process are better value.

5. Is the death benefit “high leverage”? A frequently confused point

Participating savings policy:

• Death benefit = max(guaranteed cash value + accrued reversionary bonus + terminal bonus, nominal sum assured).
• That is essentially the account’s cash value. There is no extra leverage.
• The “large sum assured” printed in the illustration is mostly nominal; it typically grows for at most ten years, after which cash value catches up with it completely.

Term life:

• Pure protection, no savings component.
• Cheap: a young, healthy person can get several million in cover for a few thousand renminbi a year.
• This is the product that genuinely offers “high leverage”, and the one to choose if the goal is to protect your family at low cost.
• Because the commission is small, Hong Kong intermediaries rarely bring it up.

6. What mainland visitors actually buy

Hong Kong Insurance Authority figures for the first three quarters of 2024 (mainland visitors):

• Whole life: 59% of policies, 80.1% of premium.
• Critical illness: 28.3% of policies.
• Medical: only 0.3% of premium, but the fastest growing (+164.2% year on year).

In other words, most of the money goes into participating whole-life policies, exactly the category this piece questions, rather than the clearer-logic critical illness and medical products.

Other product types:

• Critical illness: genuine protection with clear payout logic; Hong Kong definitions are usually broader and premiums lower.
• High-end medical: pure consumption-type cover with access to international healthcare.
• Annuities / QDAP qualifying deferred annuities: staged retirement cash flow.
• Investment-linked (ILAS): complex fee structures, controversial, under regulatory scrutiny in recent years.
• Family trusts: the genuinely ultra-wealthy (typically tens of millions and up) use trusts, not policies, as the vehicle for succession.

7. The sales scripts, decoded

1. Fear: “the renminbi will depreciate”, “mainland insurers carry default risk”. Loss aversion.
2. Scarcity: “the product is being withdrawn, rates are coming down”. Manufactured urgency, less time to think.
3. Illustrated-benefit framing: emphasise “6 to 7% compounding”, skip “non-guaranteed” and the 15-to-20-year break-even.
4. Identity and status: “standard for high-net-worth families”, “leave something for your family”. Social proof and altruism.
5. Information asymmetry: piles of jargon (British-style vs American-style dividends, terminal bonus, IRR) to project authority and obscure the fee structure.

8. Why people still buy: it isn’t all “being fooled”

1. The sale usually comes through a personal referral, on trust rather than product analysis.
2. The wrong comparison: the policy is measured against bank deposits and wealth-management products, not against stocks or index funds.
3. A real anxiety (renminbi depreciation, wanting US-dollar assets for the children) is partly met, with a lower barrier than opening a brokerage account.
4. Decision inertia: the costs (commission, opportunity cost) are invisible at signing; the benefits are vividly illustrated at the pitch.
5. Front-line agents themselves may not grasp the difference between illustrated and guaranteed benefits. “Sincere misdirection” is harder to spot.

9. The core conclusion versus SPY, or just investing

• A participating policy is a bundle of insurance and savings: poor liquidity, long lock-up, most of the return non-guaranteed, an opaque cost structure in which commission directly drags on returns.
• A low-cost index fund like SPY: liquid, near-zero fees (about 0.09%), a long-run historical return close to 10% a year, but no floor and real volatility.
• If the goal is pure capital growth, a participating policy will very likely trail SPY, because tens of percentage points of commission and running costs come off first.
• The sensible role of a participating policy is a combination of insurance cover, a specific cross-border structure, and convenient succession, not maximum return. Only people who genuinely need those structural features, and understand the limits (CRS reporting still applies; it is not a compliant route for moving mainland money offshore), should consider it.
• For the great majority of ordinary investors, a participating savings policy is worse value than direct equity investment.

---

A general product analysis compiled from public sources; not insurance, tax or investment advice. Policy terms govern; consult a licensed professional. 中文版.